News
Excited to Have Been Part of European Crohn’s and Colitis Organisation (ECCO) 2025 in Berlin, Germany.
Delighted to have been part of European Crohn’s and Colitis Organization in Berlin, Germany! We are happy to share that our research study, titled "Patient-reported outcomes in a Greek cross-sectional survey of inflammatory bowel disease patients treated with biologic...
Publication Alert: Cost-Effectiveness Analysis of Upadacitinib in Patients With Moderately to Severely Active Ulcerative Colitis in Greece
Happy to share our most recent, open-access publication ”Cost-Effectiveness Analysis of Upadacitinib in Patients With Moderately to Severely Active Ulcerative Colitis in Greece ” in Value in Health Regional Issues. Ulcerative Colitis (UC) is a chronic inflammatory...
Publication Alert:Retrospective, Non-Interventional, Multicenter Study on the Effectiveness and Safety of Intravesical Bacillus Calmette–Guerin in Patients with Non-Muscle-Invasive Bladder Cancer: Real-World Experience from Six Hospital Centers in Greece
We are delighted to share our latest real-world evidence publication, titled "Retrospective, Non-Interventional, Multicenter Study on the Effectiveness and Safety of Intravesical Bacillus Calmette–Guerin in Patients with Non-Muscle-Invasive Bladder Cancer: Real-World...
Excited to Have Been Part of ISPOR conference 2024 in Barcelona, Spain!
Delighted to have been part of ISPOR—The Professional Society for Health Economics and Outcomes Research in Barcelona, Spain! Health Through Evidence proudly presented 15 research posters at ISPOR Europe 2024, highlighting impactful studies in Health Economics, Real...
Health Through Evidence will be participating in the upcoming ISPOR – Europe 2024 conference!
We are excited to announce that Health Through Evidence will be participating in the upcoming ISPOR – International Society for Pharmaceutical Outcomes Research – Europe 2024 conference in Barcelona from 17-20 November! Health Through Evidence will be presenting 15...